Works by Frederich, Robert

Results: 35

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial.
Published in:
Diabetology & Metabolic Syndrome, 2012, v. 4, n. 1, p. 36, doi. 10.1186/1758-5996-4-36
By:
- Frederich, Robert;
- McNeill, Robert;
- Berglind, Niklas;
- Fleming, Douglas;
- Chen, Roland
Publication type:
Article
Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial.
Published in:
Diabetes Care, 2015, v. 38, n. 6, p. 1145, doi. 10.2337/dc14-2868
By:
- Leiter, Lawrence A.;
- Hwee Teoh;
- Braunwald, Eugene;
- Mosenzon, Ofri;
- Cahn, Avivit;
- Kumar, K. M. Prasanna;
- Smahelova, Alena;
- Hirshberg, Boaz;
- Stahre, Christina;
- Frederich, Robert;
- Bonnici, Francois;
- Scirica, Benjamin M.;
- Bhatt, Deepak L.;
- Raz, Itamar
Publication type:
Article
Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial.
Published in:
Diabetes Care, 2015, v. 38, n. 4, p. 696, doi. 10.2337/dc14-1850
By:
- Udell, Jacob A.;
- Bhatt, Deepak L.;
- Braunwald, Eugene;
- Cavender, Matthew A.;
- Mosenzon, Ofri;
- Steg, Ph. Gabriel;
- Davidson, Jaime A.;
- Nicolau, Jose C.;
- Corbalan, Ramon;
- Hirshberg, Boaz;
- Frederich, Robert;
- KyungAh Im;
- Umez-Eronini, Amarachi A.;
- He, Ping;
- McGuire, Darren K.;
- Leiter, Lawrence A.;
- Raz, Itamar;
- Scirica, Benjamin M.
Publication type:
Article
Long‐term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial.
Published in:
Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 583, doi. 10.1111/dom.16050
By:
- Cosentino, Francesco;
- Dagogo‐Jack, Samuel;
- Frederich, Robert;
- Cannon, Christopher P.;
- Cherney, David Z. I.;
- Mancuso, James P.;
- Wynant, Willy;
- Xing, Aiwen;
- Gantz, Ira;
- Cater, Nilo B.;
- Pratley, Richard E.
Publication type:
Article
Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study.
Published in:
Diabetes, Obesity & Metabolism, 2025, v. 27, n. 1, p. 215, doi. 10.1111/dom.16005
By:
- Amin, Neeta B.;
- Frederich, Robert;
- Tsamandouras, Nikolaos;
- Haggag, Amina Z.;
- Schuster, Tilman;
- Zmuda, Witold;
- Palmer, Alexandra;
- Vasas, Szilard;
- Buckley, Gina;
- Smith, Timothy R.;
- DuBrava, Sarah J.;
- Zhu, Qi;
- Johnson, Margot
Publication type:
Article
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
Published in:
Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3478, doi. 10.1111/dom.15687
By:
- Odutayo, Ayodele;
- Cosentino, Francesco;
- Pratley, Richard E.;
- Dagogo‐Jack, Samuel;
- McGuire, Darren K.;
- Frederich, Robert;
- Fu, Wei;
- Cannon, Christopher P.;
- Cherney, David Z. I.
Publication type:
Article
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
Published in:
Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1398, doi. 10.1111/dom.14965
By:
- Kim, Joseph M.;
- Bhatt, Deepak L.;
- Dagogo‐Jack, Samuel;
- Cherney, David Z. I.;
- Cosentino, Francesco;
- McGuire, Darren K.;
- Pratley, Richard E.;
- Liu, Chih‐Chin;
- Cater, Nilo B.;
- Frederich, Robert;
- Mancuso, James P.;
- Cannon, Christopher P.
Publication type:
Article
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin
Published in:
Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 758, doi. 10.1111/dom.14923
By:
- Corbin, Karen D.;
- Dagogo‐Jack, Samuel;
- Cannon, Christopher P.;
- Cherney, David Z.I.;
- Cosentino, Francesco;
- Frederich, Robert;
- Liu, Jie;
- Pong, Annpey;
- Lin, Jianxin;
- Cater, Nilo B.;
- Pratley, Richard E.
Publication type:
Article
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
Published in:
Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1829, doi. 10.1111/dom.14769
By:
- Segar, Matthew W.;
- Kolkailah, Ahmed A.;
- Frederich, Robert;
- Pong, Annpey;
- Cannon, Christopher P.;
- Cosentino, Francesco;
- Dagogo‐Jack, Samuel;
- McGuire, Darren K.;
- Pratley, Richard E.;
- Liu, Chih‐Chin;
- Maldonado, Mario;
- Liu, Jie;
- Cater, Nilo B.;
- Pandey, Ambarish;
- Cherney, David Z. I.
Publication type:
Article
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV.
Published in:
Diabetes, Obesity & Metabolism, 2022, v. 24, n. 7, p. 1245, doi. 10.1111/dom.14691
By:
- Dagogo‐Jack, Samuel;
- Cannon, Christopher P.;
- Cherney, David Z. I.;
- Cosentino, Francesco;
- Liu, Jie;
- Pong, Annpey;
- Gantz, Ira;
- Frederich, Robert;
- Mancuso, James P.;
- Pratley, Richard E.
Publication type:
Article
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
Published in:
Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 1114, doi. 10.1111/dom.14677
By:
- Cherney, David Z. I.;
- Cosentino, Francesco;
- Pratley, Richard E.;
- Dagogo‐Jack, Samuel;
- Frederich, Robert;
- Maldonado, Mario;
- Liu, Jie;
- Pong, Annpey;
- Liu, Chih‐Chin;
- Cannon, Christopher P.
Publication type:
Article
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
Published in:
European Heart Journal, 2023, v. 44, n. 48, p. 5163, doi. 10.1093/eurheartj/ehad639
By:
- Pandey, Ambarish;
- Kolkailah, Ahmed A;
- Cosentino, Francesco;
- Cannon, Christopher P;
- Frederich, Robert C;
- Cherney, David Z I;
- Dagogo-Jack, Samuel;
- Pratley, Richard E;
- Cater, Nilo B;
- Gantz, Ira;
- Mancuso, James P;
- McGuire, Darren K
Publication type:
Article
Severe leptin resistance in brown fat-deficient uncoupling protein promoter-driven diphtheria toxin A mice despite suppression of hypothalamic neuropeptide Y and circulating corticosterone concentrations.
Published in:
1998
By:
- Mantzoros, Christos S.;
- Frederich, Robert C.;
- Qu, Daqing;
- Lowell, Bradford B.;
- Maratos-Flier, Eleftheria;
- Flier, Jeffrey S.;
- Mantzoros, C S;
- Frederich, R C;
- Qu, D;
- Lowell, B B;
- Maratos-Flier, E;
- Flier, J S
Publication type:
journal article
Activation of β<sub>3</sub> Adrenergic Receptors Suppresses Leptin Expression and Mediates a Leptin-Independent Inhibition of Food Intake in Mice.
Published in:
Diabetes, 1996, v. 45, n. 7, p. 909, doi. 10.2337/diab.45.7.909
By:
- Mantzoros, Christos S.;
- Qu, Daqing;
- Frederich, Robert C.;
- Susulic, Vedrana S.;
- Lowell, Bradford B.;
- Maratos-Flier, Eleftheria;
- Flier, Jeffrey S.
Publication type:
Article
A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy.
Published in:
BMC Endocrine Disorders, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1472-6823-14-17
By:
- White, Judith L.;
- Buchanan, Patricia;
- Jia Li;
- Frederich, Robert
Publication type:
Article
Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.
Published in:
2013
By:
- Cook, William;
- Bryzinski, Brian;
- Slater, Jill;
- Frederich, Robert;
- Allen, Elsie
Publication type:
journal article
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials.
Published in:
Clinical Cardiology, 2021, v. 44, n. 8, p. 1139, doi. 10.1002/clc.23665
By:
- Cherney, David Z. I.;
- Dagogo‐Jack, Samuel;
- McGuire, Darren K.;
- Cosentino, Francesco;
- Pratley, Richard;
- Shih, Weichung J.;
- Frederich, Robert;
- Maldonado, Mario;
- Liu, Jie;
- Wang, Shuai;
- Cannon, Christopher P.
Publication type:
Article
Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different Devices.
Published in:
Clinical Pharmacology in Drug Development, 2019, v. 8, n. 1, p. 40, doi. 10.1002/cpdd.454
By:
- Wang, Ellen Q.;
- Plotka, Anna;
- Salageanu, Joanne;
- Baltrukonis, Daniel;
- Mridha, Khurshid;
- Frederich, Robert;
- Sullivan, Beth E.
Publication type:
Article
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ⩾ 65 years) with inadequately controlled type 2 diabetes mellitus.
Published in:
Clinical Interventions in Aging, 2013, v. 8, p. 419, doi. 10.2147/CIA.S41246
By:
- Karyekar, Chetan S.;
- Ravichandran, Shoba;
- Allen, Elsie;
- Fleming, Douglas;
- Frederich, Robert
Publication type:
Article
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
Published in:
Diabetes & Vascular Disease Research, 2011, v. 8, n. 2, p. 125, doi. 10.1177/1479164111404575
By:
- Hollander, Priscilla L;
- Jia Li;
- Frederich, Robert;
- Allen, Elsie;
- Chen, Roland
Publication type:
Article
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
Published in:
Journal of Clinical Endocrinology & Metabolism, 2023, v. 108, n. 8, p. 2042, doi. 10.1210/clinem/dgac764
By:
- Dagogo-Jack, Samuel;
- Frederich, Robert;
- Jie Liu;
- Cannon, Christopher P.;
- Shi, Harry;
- Cherney, David Z. I.;
- Cosentino, Francesco;
- Masiukiewicz, Urszula;
- Gantz, Ira;
- Pratley, Richard E.
Publication type:
Article
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials.
Published in:
Cardiovascular Diabetology, 2014, v. 13, n. 1, p. 2, doi. 10.1186/1475-2840-13-33
By:
- Iqbal, Nayyar;
- Parker, Artist;
- Frederich, Robert;
- Donovan, Mark;
- Hirshberg, Boaz
Publication type:
Article
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.
Published in:
Sleep & Breathing, 2023, v. 27, n. 2, p. 669, doi. 10.1007/s11325-022-02594-2
By:
- Wojeck, Brian S.;
- Inzucchi, Silvio E.;
- Neeland, Ian J.;
- Mancuso, James P.;
- Frederich, Robert;
- Masiukiewicz, Urszula;
- Cater, Nilo B.;
- McGuire, Darren K.;
- Cannon, Christopher P.;
- Yaggi, Henry Klar
Publication type:
Article
Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].
Published in:
2022
By:
- Cherney, David Z. I.;
- Charbonnel, Bernard;
- Cosentino, Francesco;
- Dagogo-Jack, Samuel;
- McGuire, Darren K.;
- Pratley, Richard;
- Shih, Weichung J.;
- Frederich, Robert;
- Maldonado, Mario;
- Pong, Annpey;
- Cannon, Christopher P.
Publication type:
Letter
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
Published in:
Diabetologia, 2021, v. 64, n. 6, p. 1256, doi. 10.1007/s00125-021-05407-5
By:
- Cherney, David Z. I.;
- Charbonnel, Bernard;
- Cosentino, Francesco;
- Dagogo-Jack, Samuel;
- McGuire, Darren K.;
- Pratley, Richard;
- Shih, Weichung J.;
- Frederich, Robert;
- Maldonado, Mario;
- Pong, Annpey;
- Cannon, Christopher P.
Publication type:
Article
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.
Published in:
Diabetologia, 2020, v. 63, n. 6, p. 1128, doi. 10.1007/s00125-020-05133-4
By:
- Cherney, David Z. I.;
- Heerspink, Hiddo J. L.;
- Frederich, Robert;
- Maldonado, Mario;
- Liu, Jie;
- Pong, Annpey;
- Xu, Zhi J.;
- Patel, Shrita;
- Hickman, Anne;
- Mancuso, James P.;
- Gantz, Ira;
- Terra, Steven G.
Publication type:
Article
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity.
Published in:
Diabetes Therapy, 2023, v. 14, n. 2, p. 319, doi. 10.1007/s13300-022-01345-6
By:
- Ji, Linong;
- Liu, Jie;
- Xu, Zhi Jin;
- Wei, Zhiqi;
- Zhang, Ruya;
- Malkani, Seema;
- Cater, Nilo B.;
- Frederich, Robert
Publication type:
Article
Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV.
Published in:
Diabetes Therapy, 2021, v. 12, n. 5, p. 1279, doi. 10.1007/s13300-021-01033-x
By:
- Budoff, Matthew J.;
- Davis, Timothy M. E.;
- Palmer, Alexandra G.;
- Frederich, Robert;
- Lawrence, David E.;
- Liu, Jie;
- Gantz, Ira;
- Derosa, Giuseppe
Publication type:
Article
Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials.
Published in:
Diabetes Therapy, 2020, v. 11, n. 6, p. 1347, doi. 10.1007/s13300-020-00803-3
By:
- Patel, Shrita;
- Hickman, Anne;
- Frederich, Robert;
- Johnson, Susan;
- Huyck, Susan;
- Mancuso, James P.;
- Gantz, Ira;
- Terra, Steven G.
Publication type:
Article
Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial.
Published in:
American Journal of Nephrology, 2022, v. 53, n. 7, p. 516, doi. 10.1159/000524889
By:
- Cherney, David Z.I.;
- Cosentino, Francesco;
- Dagogo-Jack, Samuel;
- McGuire, Darren K.;
- Pratley, Richard E.;
- Frederich, Robert;
- Maldonado, Mario;
- Liu, Chih-Chin;
- Pong, Annpey;
- Cannon, Christopher P.
Publication type:
Article
796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV.
Published in:
Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-796-P
By:
- CHERNEY, DAVID;
- COSENTINO, FRANCESCO;
- MCGUIRE, DARREN K.;
- CHARBONNEL, BERNARD;
- DAGOGO-JACK, SAMUEL;
- PRATLEY, RICHARD E.;
- SHIH, WEICHUNG J.;
- MALDONADO, MARIO;
- PONG, ANNPEY;
- GANTZ, IRA;
- FREDERICH, ROBERT;
- MANCUSO, JAMES P.;
- MASIUKIEWICZ, URSZULA;
- CANNON, CHRISTOPHER P.
Publication type:
Article
786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV.
Published in:
Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-786-P
By:
- DAGOGO-JACK, SAMUEL;
- PRATLEY, RICHARD E.;
- CHERNEY, DAVID;
- CHARBONNEL, BERNARD;
- MCGUIRE, DARREN K.;
- COSENTINO, FRANCESCO;
- SHIH, WEICHUNG J.;
- LIU, JIE;
- FREDERICH, ROBERT;
- MANCUSO, JAMES P.;
- RAJI, ANNASWAMY;
- GANTZ, IRA
Publication type:
Article
785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV.
Published in:
Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-785-P
By:
- DAGOGO-JACK, SAMUEL;
- FREDERICH, ROBERT;
- CHARBONNEL, BERNARD;
- LIU, JIE;
- CANNON, CHRISTOPHER P.;
- SHI, HARRY;
- MCGUIRE, DARREN K.;
- CHERNEY, DAVID;
- COSENTINO, FRANCESCO;
- SHIH, WEICHUNG J.;
- MASIUKIEWICZ, URSZULA;
- GANTZ, IRA;
- PRATLEY, RICHARD E.
Publication type:
Article
783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV.
Published in:
Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-783-P
By:
- CHARBONNEL, BERNARD;
- DAGOGO-JACK, SAMUEL;
- CANNON, CHRISTOPHER P.;
- CHERNEY, DAVID;
- COSENTINO, FRANCESCO;
- MCGUIRE, DARREN K.;
- SHIH, WEICHUNG J.;
- LIU, JIE;
- PONG, ANNPEY;
- GANTZ, IRA;
- FREDERICH, ROBERT;
- MANCUSO, JAMES P.;
- PRATLEY, RICHARD E.
Publication type:
Article
1197-P: Two-Year Effects of Ertugliflozin on Renal Function.
Published in:
Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1197-P
By:
- CHERNEY, DAVID;
- HEERSPINK, HIDDO L.;
- FREDERICH, ROBERT;
- MALDONADO, MARIO;
- PONG, ANNPEY;
- XU, ZHI JIN;
- LIU, JIE;
- MANCUSO, JAMES P.;
- GANTZ, IRA;
- TERRA, STEVEN G.
Publication type:
Article